About STRATA Skin Sciences, Inc.
https://www.strataskinsciences.comSTRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.
CEO
Dolev Rafaeli
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-06-07 | Reverse | 1:10 |
| 2017-04-07 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : D+
Price Target
Institutional Ownership
Summary
Showing Top 1 of 1
About STRATA Skin Sciences, Inc.
https://www.strataskinsciences.comSTRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $6.93M ▼ | $6.04M ▼ | $-1.62M ▲ | -23.41% ▲ | $-0.36 ▲ | $-173K ▲ |
| Q2-2025 | $7.66M ▲ | $6.53M ▲ | $-2.49M ▼ | -32.48% ▲ | $-0.6 ▼ | $-693K ▼ |
| Q1-2025 | $6.81M ▼ | $5.66M ▼ | $-2.43M ▲ | -35.7% ▲ | $-0.06 ▲ | $-641K ▲ |
| Q4-2024 | $9.58M ▲ | $9.98M ▲ | $-4.5M ▼ | -46.96% ▼ | $-0.12 ▼ | $-2.84M ▼ |
| Q3-2024 | $8.8M | $6.96M | $-2.12M | -24.12% | $-0.05 | $-265K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $7.08M ▲ | $30.72M ▼ | $29.4M ▼ | $1.31M ▲ |
| Q2-2025 | $5.97M ▼ | $30.72M ▼ | $30.41M ▼ | $308K ▼ |
| Q1-2025 | $6.51M ▼ | $34.26M ▼ | $31.59M ▲ | $2.67M ▼ |
| Q4-2024 | $7.26M ▲ | $36.16M ▼ | $31.18M ▲ | $4.97M ▼ |
| Q3-2024 | $7.06M | $40.2M | $30.86M | $9.34M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.62M ▲ | $-64K ▲ | $-1.02M ▼ | $2.19M ▲ | $1.11M ▲ | $-1.08M ▲ |
| Q2-2025 | $-2.49M ▼ | $-1.94M ▼ | $61K ▲ | $0 | $-1.88M ▼ | $-1.88M ▼ |
| Q1-2025 | $-2.43M ▲ | $-550K ▼ | $-199K ▲ | $0 | $-749K ▼ | $-749K ▼ |
| Q4-2024 | $-4.5M ▼ | $703K ▲ | $-504K ▼ | $0 ▼ | $199K ▼ | $199K ▲ |
| Q3-2024 | $-2.12M | $-302K | $-62K | $1.94M | $1.58M | $-364K |
Revenue by Products
| Product | Q2-2024 | Q4-2024 | Q3-2024 | Q1-2025 |
|---|---|---|---|---|
 Dermatology Procedures Equipment | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Dermatology Recurring Procedures | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
Revenue by Geography
| Region | Q3-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 CHINA | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Domestic | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
 Middle East | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $0 ▲ | $10.00M ▲ | $0 ▼ | $10.00M ▲ |
| Foreign | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Dolev Rafaeli
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-06-07 | Reverse | 1:10 |
| 2017-04-07 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : D+
Price Target
Institutional Ownership
Summary
Showing Top 1 of 1